Grothey Spotlights the Growing HER2+ Paradigm in GI Cancers
Season 4, Episode 35, Feb 25, 2021, 11:28 PM
In our exclusive interview, Dr. Grothey discusses the excitement surrounding HER2-directed therapies in gastrointestinal malignancies, the approval of trastuzumab deruxtecan in HER2-positive metastatic gastric/gastroesophageal junction cancer, and the investigational agents patritumab deruxtecan and zanidatamab that are poised to further advance the paradigm.